Your session is about to expire
← Back to Search
Radiation
Radiosurgery for Essential Tremor
N/A
Waitlist Available
Led By John Fiveash, MD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients must be at least 18 years of age.
Patients must have an ECOG status of 0, 1, or 2.
Must not have
Patients who have had prior radiosurgery or therapeutic brain radiation therapy.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline up to 36 months following completion of radiosurgery
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a non-surgical radiation treatment to help people with severe tremors from Essential Tremor or Parkinson's Disease who can't have traditional brain surgery. The treatment aims to reduce shaking by targeting specific brain areas with precise radiation. This minimally invasive alternative to traditional brain surgery is designed for treating tremors in conditions like Essential Tremor and Parkinson's Disease.
Who is the study for?
This trial is for adults with severe, treatment-resistant shaking (tremor) due to Essential Tremor or Parkinson's Disease who can't have deep brain stimulation because of health issues or personal choice. They should be able to perform daily activities with minimal assistance (ECOG status 0-2).
What is being tested?
The study tests a non-invasive procedure called Virtual Cone Radiosurgical Thalamotomy, which targets the brain area causing tremors. It aims to reduce tremors in patients who haven't improved with medication and aren't suitable for surgery.
What are the potential side effects?
Potential side effects may include temporary swelling or permanent changes in a small part of the brain treated, which could affect other body functions controlled by that area. MRI scans are used, so risks associated with MRI also apply.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
I am able to care for myself and up and about more than 50% of my waking hours.
Select...
I have severe tremor from Parkinson's or essential tremor and cannot or choose not to have DBS surgery.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have had brain radiation therapy before.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from baseline up to 36 months following completion of radiosurgery
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline up to 36 months following completion of radiosurgery
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Tremor
Secondary study objectives
Changes in resting-state functional MRI (fMRI) and diffusion tensor patterns associated with Radiosurgical thalamotomy
Thalamic structure
Mean of Quality of Life Scores measured by PROMIS Upper Extremity Questionnaire
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: 130 Gy Radiation & Unframed Virtual ConeExperimental Treatment1 Intervention
130 Gy Virtual Cone Radiosurgery Unframed (Face Mask)
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Essential Tremor (ET) include neuromodulation and radiosurgical thalamotomy. Neuromodulation, such as noninvasive nerve stimulation, works by modulating abnormal neural activity to reduce tremor severity.
Radiosurgical thalamotomy, like the frameless Virtual Cone Radiosurgical Thalamotomy, targets the ventral intermediate nucleus of the thalamus with precise radiation to create a lesion, disrupting the neural circuits responsible for tremor. This is particularly important for ET patients who are not candidates for deep brain stimulation (DBS) due to surgical risks, offering a non-invasive yet effective treatment option.
Radiotherapy of non-tumoral refractory neurological pathologies.Vim stereotactic radiosurgical thalamotomy for drug-resistant idiopathic Holmes tremor: a case report.Advances in diagnosis and treatment of trigeminal neuralgia.
Radiotherapy of non-tumoral refractory neurological pathologies.Vim stereotactic radiosurgical thalamotomy for drug-resistant idiopathic Holmes tremor: a case report.Advances in diagnosis and treatment of trigeminal neuralgia.
Find a Location
Who is running the clinical trial?
University of Alabama at BirminghamLead Sponsor
1,656 Previous Clinical Trials
2,444,333 Total Patients Enrolled
John Fiveash, MDPrincipal InvestigatorUniversity of Alabama at Birmingham
6 Previous Clinical Trials
336 Total Patients Enrolled
Markus Bredel, MD, PhDPrincipal Investigator - University of Alabama at Birmingham
University of Alabama at Birmingham
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You cannot have an MRI because of a medical reason, such as having a pacemaker.I am 18 years old or older.I have had brain radiation therapy before.I am able to care for myself and up and about more than 50% of my waking hours.I have severe tremor from Parkinson's or essential tremor and cannot or choose not to have DBS surgery.
Research Study Groups:
This trial has the following groups:- Group 1: 130 Gy Radiation & Unframed Virtual Cone
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.